Expression of PLK1-inhibited or siRNA-treated showed antitumor activity against prostate, breast, cervical, colon, and lung cancer cells [66,67,68], etc. PLK1 has a potential application strategy in cancer therapy [66,67,68,69]. This evidence concerns the gene PLK1 and lung cancer.